WO2002081520A3 - Single chain dimeric polypeptides derived from the vegf family - Google Patents

Single chain dimeric polypeptides derived from the vegf family Download PDF

Info

Publication number
WO2002081520A3
WO2002081520A3 PCT/DK2002/000233 DK0200233W WO02081520A3 WO 2002081520 A3 WO2002081520 A3 WO 2002081520A3 DK 0200233 W DK0200233 W DK 0200233W WO 02081520 A3 WO02081520 A3 WO 02081520A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
vegf
binding
polypeptide
single chain
Prior art date
Application number
PCT/DK2002/000233
Other languages
French (fr)
Other versions
WO2002081520A2 (en
Inventor
Thomas Peter Boesen
Torben Halkier
Original Assignee
Maxygen Holdings Ltd
Thomas Peter Boesen
Torben Halkier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Holdings Ltd, Thomas Peter Boesen, Torben Halkier filed Critical Maxygen Holdings Ltd
Priority to AU2002338313A priority Critical patent/AU2002338313A1/en
Publication of WO2002081520A2 publication Critical patent/WO2002081520A2/en
Publication of WO2002081520A3 publication Critical patent/WO2002081520A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention relates to a single-chain dimeric polypeptide which binds to an extracellular ligand-binding domain of a VEGF type 2 receptor (KDR) or a VEGF type 3 receptor (Flt-4), the polypeptide comprising two receptor-binding sites of which one is capable of binding to a ligand-binding domain of the receptor and one is incapable of effectively binding to a ligand-binding domain of the receptor, and wherein at least one monomer of the dimeric polypeptide is derived from VEGF, VEGF-C or VEGF-D, whereby the single-chain dimeric polypeptide is capable of binding to the receptor, but incapable of activating the receptor. The polypeptide functions as a receptor antagonist for prevention or treatment of a disease or condition involving increased signal transduction from or increased activation of the KDR and/or Flt-4 receptor, e.g. to inhibit angiogenesis or lymphangiogenesis.
PCT/DK2002/000233 2001-04-06 2002-04-08 Single chain dimeric polypeptides derived from the vegf family WO2002081520A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002338313A AU2002338313A1 (en) 2001-04-06 2002-04-08 Single chain dimeric polypeptides derived from the vegf family

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28223901P 2001-04-06 2001-04-06
US60/282,239 2001-04-06
DKPA200100578 2001-04-06
DKPA200100578 2001-04-06

Publications (2)

Publication Number Publication Date
WO2002081520A2 WO2002081520A2 (en) 2002-10-17
WO2002081520A3 true WO2002081520A3 (en) 2003-05-01

Family

ID=26069004

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2002/000233 WO2002081520A2 (en) 2001-04-06 2002-04-08 Single chain dimeric polypeptides derived from the vegf family

Country Status (2)

Country Link
AU (1) AU2002338313A1 (en)
WO (1) WO2002081520A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068802A2 (en) 2002-02-11 2003-08-21 Zymogenetics, Inc. Materials and methods for preparing dimeric growth factors
CN1903880B (en) * 2006-08-02 2010-05-12 中国人民解放军军事医学科学院基础医学研究所 Antitumour vascular endothelial growth factor VEGF-E antigen, its coding gene and application
WO2010005527A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
US8741839B2 (en) 2009-01-18 2014-06-03 The Board Of Trustees Of The Leland Stanford Junior University Polypeptides targeting vascular endothelial growth factor receptor-2 and αvβ3 integrin
US9963495B2 (en) 2015-10-27 2018-05-08 The Board Of Trustees Of The Leland Stanford Junior University Polypeptides targeting vascular endothelial growth factor receptor and prostate specific membrane antigen
JP6936808B2 (en) * 2015-12-03 2021-09-22 ナショナル ヘルス リサーチ インスティテューツＮａｔｉｏｎａｌ Ｈｅａｌｔｈ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅｓ Fusion proteins, nucleic acid molecules, host cells, pharmaceutical compositions, and how to use the pharmaceutical compositions
WO2017139417A1 (en) 2016-02-08 2017-08-17 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008313A1 (en) * 1995-08-25 1997-03-06 Genentech, Inc. Variants of vascular endothelial cell growth factor, their uses, and processes for their production
WO1998016551A2 (en) * 1996-10-17 1998-04-23 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties
WO2001012809A2 (en) * 1999-08-13 2001-02-22 Crucell Holland B.V. Heterodimeric vegf variants used for inhibiting angiogenesis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008313A1 (en) * 1995-08-25 1997-03-06 Genentech, Inc. Variants of vascular endothelial cell growth factor, their uses, and processes for their production
WO1998016551A2 (en) * 1996-10-17 1998-04-23 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties
WO2001012809A2 (en) * 1999-08-13 2001-02-22 Crucell Holland B.V. Heterodimeric vegf variants used for inhibiting angiogenesis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SIEMEISTER G ET AL: "AN ANTAGONISTIC VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) VARIANT INHIBITS VEGF-STIMULATED RECEPTOR AUTOPHOSPHORYLATION AND PROLIFERATION OF HUMAN ENDOTHELIAL CELLS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 95, no. 8, 14 April 1998 (1998-04-14), pages 4625 - 4629, XP000876737, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
AU2002338313A1 (en) 2002-10-21
WO2002081520A2 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
ATE260299T1 (en) DESIGN OF HORMONE-LIKE ANTIBODIES WITH AGONIST AND ANTAGONIST PROPERTIES
WO2002022153A3 (en) Use of a polypeptide comprising the extracellular domains of il-20rb for the treatment of inflammation
WO2006052723A3 (en) G protein coupled receptor agonists and antagonists and methods of use
WO2004069158A3 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
WO2001072829A3 (en) Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
WO2002089729A3 (en) Fused heterocyclic compounds
WO2002081520A3 (en) Single chain dimeric polypeptides derived from the vegf family
WO2004100875A3 (en) Benzimidazoles, compositions containing such compounds and methods of use
WO2002024909A3 (en) Receptor nucleic acids and polypeptides
PL332034A1 (en) Monoclonal antibodies against extracellular domain of human vegf (kdr) receptor
BR9912406A (en) Substituted anilide compounds and methods
WO2000064946A3 (en) Compositions and methods for cancer treatment by selectively inhibiting vegf
WO2005077981A3 (en) Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
ATE359300T1 (en) FLT4 (VEGFR-3) AS A TARGET FOR CANCER DETECTION AND ANTI-CANCER TREATMENT
DK1047781T3 (en) IL-18 receptors
WO2002014500A3 (en) Human genes and gene expression products
WO2001066753A3 (en) Human genes and gene expression products
WO2004005262A8 (en) New neuropeptide y y5 receptor antagonists
WO2006046072A3 (en) VWFA AND/OR ANT_IG DOMAIN CONTAINING PROTEINS
WO2005087177A3 (en) Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
WO2004085617A3 (en) Timp3 as vegf inhibitor
EP1283217A3 (en) Antibodies against the IL-8 receptor, and their therapeutic uses
PT1137413E (en) NAO-PEPTIDIC ANTAGONISTS OF THE GLP-1 RECEPTOR AND METHODS OF USE
WO2002102839A3 (en) Novel g-protein coupled receptors and dna sequences thereof
HK1037141A1 (en) Use of endothelin receptor antagonists for producing drugs for controlling obesity.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP